natgillin/translations-raw huggingface dataset:
During clinical development of Ilaris in over 2,300 patients, no anaphylactoid or anaphylactic reactions were reported.
V času kliničnega razvoja zdravila Ilaris pri več kot 2.300 bolnikih o primerih anafilaktoidnih ali anafilaktičnih reakcij niso poročali.
During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.
Med terenskimi kliničnimi testiranji niso opazili nobenih interakcij z rutinsko uporabljenimi zdravili za uporabo v veterinarski medicini.
During clinical studies 183 cancer patients and 96 healthy volunteers were exposed to Nivestim.
Med kliničnimi študijami je bilo zdravilu Nivestim izpostavljenih 183 rakavih bolnikov in 96 zdravih prostovoljcev.
During clinical studies 541 cancer patients and 188 healthy volunteers were exposed to Ratiograstim.
Med kliničnimi študijami je bilo zdravilu Ratiograstim izpostavljenih 541 bolnikov z rakom in 188 zdravih prostovoljcev.
During clinical studies 541 cancer patients and 188 healthy volunteers were exposed to Tevagrastim.
Med kliničnimi študijami je bilo zdravilu Tevagrastim izpostavljenih 541 bolnikov z rakom in 188 zdravih prostovoljcev.
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration..
Med kliničnimi raziskavami je plazemski nivo maropitanta pokazal učinkovitost 1 uro po dajanju.
During clinical studies with CEPROTIN, a total of 6 non-serious adverse drug reactions (ADRs) were reported in 3 of 225 patients enrolled.
Med kliničnimi študijami z zdravilom CEPROTIN so pri 3 od 225 bolnikov, vključenih v te študije, poročali o skupaj 6 neresnih neželenih učinkih (ADR).
During clinical studies with Nuwiq in previously treated paediatric (2 to 11 years, n = 58), adolescent (12 to 17 years, n = 3) and adult patients (n = 74) with severe haemophilia A, a total of 8 adverse drug reactions (ADRs) (6 in adults, 2 in children) were reported in 5 patients (3 adults, 2 children).
Med kliničnimi študijami z zdravilom Nuwiq pri predhodno zdravljenih otrocih (od 2 do 11 let, n = 58), mladostnikih (od 12 do 17 let, n = 3) in odraslih bolnikih (n = 74) s hudo hemofilijo A so pri 5 bolnikih (3 odrasli, 2 otroka) poročali o skupno 8 neželenih učinkih zdravila (6 pri odraslih, 2 pri otrocih).
During clinical studies, blood samples from patients with Dupuytren’s contracture and Peyronie’s disease were tested at multiple time points for antibodies to the protein components of the medicinal product (AUX-I and AUX-II).
Med kliničnimi študijami so večkrat testirali krvne vzorce bolnikov z Dupuytrenovo kontrakturo in Peyroniejevo boleznijo na prisotnost protiteles proti beljakovinskim komponentam zdravila (AUX-I in AUX-II).
During clinical studies, dose-dependent increases in serum creatinine occurred in about 36% of patients, though most remained within the normal range.
V kliničnih študijah je pri približno 36 % bolnikov prišlo do od odmerka odvisnega zvišanja koncentracije kreatinina v serumu, čeprav je ta večinoma ostala v mejah normalnih vrednosti.
During clinical studies, episodes of headache and insomnia have been reported (7.7 % to 8.4%).
Med kliničnimi študijami so poročali o epizodah glavobolov in nespečnosti (7,7 % do 8,4 %).
During clinical studies, more patients on Ultibro Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
V kliničnih študijah so klinično opazne spremembe v koncentraciji glukoze v krvi pogosteje opažali pri bolnikih, ki so jemali zdravilo Ultibro Breezhaler v priporočenem odmerku, (4,1 %) v primerjavi s tistimi, ki so jemali placebo (2,3 %).
During clinical studies, more patients on Ulunar Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
V kliničnih študijah so klinično opazne spremembe v koncentraciji glukoze v krvi pogosteje opažali pri bolnikih, ki so jemali zdravilo Ulunar Breezhaler v priporočenem odmerku, (4,1 %) v primerjavi s tistimi, ki so jemali placebo (2,3 %).
During clinical studies, more patients on Xoterna Breezhaler experienced clinically notable changes in blood glucose (4.1%) at the recommended dose than on placebo (2.3%).
V kliničnih študijah so klinično opazne spremembe v koncentraciji glukoze v krvi pogosteje opažali pri bolnikih, ki so jemali zdravilo Xoterna Breezhaler v priporočenem odmerku, (4,1 %) v primerjavi s tistimi, ki so jemali placebo (2,3 %).
During clinical trials in adult and adolescent patients 12 years of age and older, the most commonly reported adverse reactions were headaches and injection site reactions, including injection site pain, swelling, erythema and pruritus.
Med kliničnimi preskušanji pri odraslih in mladostnikih, starih 12 let ali več, so bile neželene reakcije, o katerih so najpogosteje poročali, glavoboli in reakcije na mestu aplikacije, med drugim bolečina, oteklina, eritem, srbenje na mestu injiciranja.
During clinical trials with Ilaris in CAPS patients mean values for haemoglobin increased and those for white blood cell, neutrophils and platelets decreased.
V kliničnih preskušanjih z zdravilom Ilaris pri bolnikih s CAPS so se njihove vrednosti hemoglobina zvišale, vrednosti levkocitov, nevtrofilcev in trombocitov pa znižale.
During clinical trials with intravenous busulfan administered as 0.80 mg/kg four-times daily, 90% of patients AUCs were below the upper AUC limit (1500 µmol/L.minute) and at least 80% were within the targeted therapeutic window (900-1500 µmol/L.minute).
Med kliničnimi preskušanji z intravensko uporabo busulfana v odmerku 0,80 mg/kg štirikrat dnevno je bilo 90 % bolnikov pod zgornjo mejo površine pod krivuljo (1.500 µmol/l.minuto) in vsaj 80 % bolnikov je bilo znotraj ciljnega terapevtskega območja (900—1.500 µmol/.minuto).
During clinical trials with Kovaltry in approximately 200 paediatric and adult patients diagnosed with severe haemophilia A (FVIII < 1 %) with previous exposure to factor VIII concentrates ≥ 50 ED, no case of inhibitor occurred.
V kliničnih preskušanjih z zdravilom Kovaltry pri približno 200 pediatričnimi in odraslimi bolniki z diagnozo hude hemofilije A (FVIII < 1 %), ki so bili predhodno izpostavljeni koncentratom faktorja VIII ≥ 50 ED ni bilo primerov nastanka inhibitorjev.
During clinical trials with Kovaltry in approximately 200 paediatric and adult patients diagnosed with severe haemophilia A (FVIII < 1%) with previous exposure to factor VIII concentrates ≥ 50 ED, no case of inhibitor occurred.
V kliničnih preskušanjih z zdravilom Kovaltry pri približno 200 pediatričnih in odraslih bolnikih z diagnozo hude hemofilije A (FVIII < 1 %), ki so bili predhodno izpostavljeni koncentratom faktorja VIII ≥ 50 ED ni bilo primerov nastanka inhibitorjev.
During clinical trials with Nonafact conducted in previously treated patients development of inhibitors was not reported.
V kliničnih preskušanjih zdravila Nonafact, ki so jih opravili pri predhodno zdravljenih bolnikih, niso poročali o pojavu inhibitorjev.
During clinical trials, a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose.
Med kliničnimi preskušanji je bil kot polnilni odmerek pomotoma uporabljen en 400-mg odmerek anidulafungina.
During clinical trials, most of the smaller size dogs (<10 kg) maintained suppressed levels of testosterone for more than 12 months following implantation.
Med kliničnimi preskusi so se pri večini manjših psov (<10 kg) vzdrževale znižane koncentracije testosterona več kot 12 mesecev po implantaciji.
During clinical trials, patients who failed to show a virologic response after 6 months of treatment (HCV- RNA below lower limit of detection) did not become sustained virologic responders (HCV-RNA below lower limit of detection six months after withdrawal of treatment).
V kliničnih raziskavah tisti bolniki, ki po 6 mesecih zdravljenja niso pokazali virološkega odziva (HCV- RNA pod spodnjo mejo detekcije), tudi kasneje niso postali virološko odzivni (HCV-RNA pod spodnjo mejo detekcije 6 mesecev po prenehanju zdravljenja).
During clinical trials, patients who failed to show a virologic response after 6 months of treatment (HCV- RNA below lower limit of detection) did not become sustained virologic responders (HCV-RNA below lower limit of detection six months after withdrawal of treatment).
V kliničnih raziskavah tisti bolniki, ki po 6 mesecih zdravljenja niso pokazali virološkega odziva (HCV- RNA pod spodnjo mejo detekcije), tudi kasneje postali virološko odzivni (HCV-RNA pod spodnjo mejo detekcije 6 mesecev po prenehanju zdravljenja).
During clinical trials, patients who failed to show a virologic response after 6 months of treatment (HCV-RNA below lower limit of detection) did not become sustained virologic responders (HCV- RNA below lower limit of detection six months after withdrawal of treatment).
Bolniki, pri katerih v kliničnih preskušanjih po 6 mesecih zdravljenja ni prišlo do virološkega odziva (HCV-RNA pod spodnjo mejo detekcije), tudi kasneje niso dosegli trajnega virološkega odziva (HCV- RNA pod spodnjo mejo detekcije 6 mesecev po prenehanju zdravljenja).
During clinical trials, the most frequently reported adverse reactions were nausea/vomiting (73%), leucopoenia (70%), alopecia (66%), neutropenia (46%), asthenia/fatigue (46%), stomatitis/mucositis (42%), thrombocytopenia (31%) and anaemia (30%).
Med kliničnimi preskušanji so bili najpogosteje poročani neželeni učinki slabost/bruhanje (73 %), levkopenija (70 %), alopecija (66 %), nevtropenija (46 %), astenija/utrujenost (46 %), stomatitis/mukozitis (42 %), trombocitopenija (31 %) in anemija (30 %).
during clinical trials† and ‡
so poročali med kliničnimi preskušanji† in
During combination therapy for up to 48 weeks with interferon alfa- 2b and ribavirin, growth inhibition was observed that resulted in reduced final adult height in some patients.
V času kombinirane terapije z interferonom alfa-2b in ribavirinom, ki je trajala do 48 tednov, so opazili zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo končno telesno višino v odrasli dobi.
During combination therapy for up to 48 weeks with interferon alfa- 2b and ribavirin, growth inhibition was observed that resulted in reduced final adult height in some patients.
V času kombinirane terapije z interferonom alfa-2b in ribavirinom, ki je trajala do 48 tednov, so opazili zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo telesno višino.
During concomitant therapy with amlodipine at the recommended dose no clinical evidence of hypotension was observed.
Med sočasnim zdravljenjem s priporočenimi odmerki amlodipina niso opazili kliničnih znakov hipotenzije.
During concomitant therapy with xanthine agents, serum theophylline levels must be monitored and dosage adjusted if necessary.
Med sočasno terapijo s ksantinskimi učinkovinami morate spremljati serumsko koncentracijo teofilina in po potrebi prilagoditi odmerek zdravila.
During contrast-enhanced echocardiography, serious cardiopulmonary reactions, including fatalities, have occurred during or within 30 minutes of Luminity administration in patients including those with severe cardiac and pulmonary diseases (see section 4.8).
Med izvajanjem kontrastne ehokardiografije ali v 30 minutah po uporabi zdravila Luminity so pri bolnikih, vključno z bolniki s hudo boleznijo srca in pljuč, poročali o pojavu hudih kardiopulmonalnih reakcij, tudi s smrtnimi izidi (glejte poglavje 4.8).
During conversion of GSH conjugates to N-acetylcysteine conjugates, GSH, cysteinylglycine, and cysteine conjugates are formed.
Med pretvorbo konjugatov GSH (growth stimulating factor) v konjugate N-acetilcisteina se oblikujejo GSH, cisteinilglicin in konjugati cisteina.
During conversion of GSH conjugates to N-acetylcysteine conjugates, GSH, cysteinylglycine, and cysteine conjugates are formed.
Med pretvorbo konjugatov GSH (growth- stimulating hormone) v konjugate N-acetilcisteina se oblikujejo GSH, cisteinilglicin in konjugati cisteina.
During Cycle 2, the incidence of IRRs was lower in patients receiving G+B (24%) compared to patients receiving bendamustine (B) alone (32%).
Incidenca reakcij, povezanih z infuzijo, je bila med 2. ciklusom nižja v skupini, ki je prejemala G + B (24 %), kot v skupini, ki je prejemala bendamustin (B) sam (32 %).
During Cycles 5 to 8 on both arms, dexrazoxane (dosed at a ratio of 10:1 to the administered dose of doxorubicin) could be administered on Day 1 of each cycle at the investigator’s discretion to reduce potential doxorubicin-related cardiotoxicity.
Pri obeh skupinah je med 5. in 8. ciklom preiskovalec lahko 1. dan vsakega izmed ciklov lahko apliciral deksrazoksan (v razmerju 10 : 1 glede na aplicirani odmerek doksorubicina), da bi se zmanjšala možnost kardiotoksičnosti, povezane z doksorubicinom.
During dose escalation in pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt).
Med povečevanjem odmerka v ključnih študijah so učinek zasledili ob odmerku 1,1 mg pramipeksola (1,5 mg soli) na dan.
During dose escalation in three pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt).
Pri povečevanju odmerka so v treh ključnih študijah opazili učinkovitost pri dnevnem odmerku 1,1 mg pramipeksola (1,5 mg soli) in več.
During dose titration, serum calcium levels should be monitored frequently, and within 1 week of initiation or dose adjustment of Parareg.
Ravni kalcija v krvi je treba meriti pogosto in v enem tednu po vsaki prilagoditvi odmerka zdravila Parareg.
During double- blind treatment, the total follow-up was 1104 patient-years in the group receiving ISENTRESS
Med dvojno slepim zdravljenjem so bolnike v skupini, ki je prejemala zdravilo ISENTRESS v odmerku 400 mg dvakrat na dan, skupno spremljali
During double-blind treatment, mean change in body weight from baseline to last visit was -0.2 kg for Abilify Maintena and -0.4 kg for placebo (p = 0.812).
Med dvojno slepim zdravljenjem je bila mediana spremembe v telesni masi od izhodiščne vrednosti do zadnjega obiska −0,2 kg za zdravilo Abilify Maintena in −0,4 kg za placebo (p = 0,812).
During double-blind treatment, the total follow-up was 708 patient-years in the group receiving ISENTRESS 400 mg twice daily, and 244 patient-years in the group receiving placebo.
Med dvojno slepim zdravljenjem so bolnike v skupini, ki je prejemala zdravilo ISENTRESS v odmerku 400 mg dvakrat na dan, skupno spremljali 708 bolnikov-let (patient-years), bolnike v skupini, ki je prejemala placebo, pa 244 bolnikov-let.
During follow up
med spremljanjem
During four double blind clinical trials of 24-week duration 1,237 patients have received treatment with co-administered fenofibrate and simvastatin.
V štirih dvojno slepih kliničnih preskušanjih, ki so trajala 24 tednov, je 1237 bolnikov sočasno prejemalo fenofibrat in simvastatin.
During handling and preparation of admixtures, Torisel should be protected from excessive room light and sunlight.
Med ravnanjem z zdravilom in pripravo raztopine je treba zdravilo Torisel varovati pred močno sobno in sončno svetlobo.
During handling and preparation of admixtures, Torisel should be protected from excessive room light and sunlight.
Med ravnanjem z zdravilom in pripravo zdravila je treba zdravilo Torisel varovati pred močno sobno in sončno svetlobo.
During handling avoid excessive fluid loss from the prepared sponges.
Pazite, da med ravnanjem s pripravljenimi gobicami iz njih ne izteče preveč tekočine.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose.
Med zdravljenjem okužbe z virusom HIV se lahko poveča telesna masa ter zviša koncentracija lipidov n glukoze v krvi.
During in vitro abacavir selection the M184V mutation occurred first and resulted in about a 2 fold increase in IC50, below the abacavir clinical cut-off of 4.5 fold change.
Med selekcijo za abakavir in vitro se je selekcija za mutacijo M184V pojavila prva in je povzročila 2-kratno povečanje IC50 pod klinično presečno 4,5-kratno spremembo občutljivosti na abakavir.
During in vitro studies, cloned human cardiac potassium channels (HERG) were inhibited by 30% at the highest concentrations of lopinavir/ritonavir tested, corresponding to a lopinavir exposure 7-fold total and 15-fold free peak plasma levels achieved in humans at the maximum recommended therapeutic dose.
Med študijami in vitro so največje preizkušene koncentracije lopinavirja/ritonavirja zavrle klonirane človeške srčne kanale za kalij (HERG) za 30%; izpostavljenost ustreza izpostavljenosti lopinavirju ob 7-kratni celotni ravni in 15-kratni prosti plazemski ravni, doseženi pri ljudeh z največjim priporočenim terapevtskim odmerkom.
During induction, the planned treatment interval for Gazyvaro should be maintained between doses.
Med indukcijo je treba med odmerki vzdrževati načrtovani terapevtski interval za zdravilo Gazyvaro.
During Inflectra treatment, other concomitant therapies, e.g. corticosteroids and immunosuppressants should be optimised.
Pri zdravljenju z zdravilom Inflectra morajo biti druge sočasne terapije, npr. s kortikosteroidi in zdravili za zaviranje imunske odzivnosti, optimalne.
During initial treatment apply the cream twice daily.
Na začetku zdravljenja nanašajte kremo dvakrat na dan.
During injection, you may hear one or more clicks – this is a normal device operation.
Med injiciranjem lahko slišite enega ali več klikov – to je običajno delovanje medicinskega pripomočka.
During intercurrent illness, there should be high awareness of the risk of developing acute adrenal insufficiency.
Med sočasno boleznijo je treba zelo paziti na tveganje za razvoj akutne adrenalne insuficience.
During intercurrent respiratory illness (e.g. bronchitis, upper respiratory tract infections) close monitoring of blood glucose concentrations and dose adjustment may be required on an individual basis (see section 4.4).
Med interkurentno boleznijo dihal (npr. bronhitis, infekcije zgornjih dihal) utegne biti potrebno natančno spremljanje koncentracij glukoze v krvi in prilagajanje odmerka na individualni podlagi (glejte poglavje 4.4).
During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for dogs and routinely used veterinary medicinal products were observed.
Med laboratorijskimi in kliničnimi testiranji niso opazili medsebojnih delovanj med zdravilom Bravecto kožni nanos, raztopina za pse, in drugimi zdravili za uporabo v veterinarski medicini, ki se uporabljajo rutinsko.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
Odmerek, pri katerem ni bilo neželenih učinkov pri mladičih v času dojenja, je bil 5 mg/kg na dan.
During long term use cutaneous vasculitis has been reported in 2% of SCN patients.
Med dolgotrajno uporabo zdravila so poročali o kožnem vaskulitisu pri 2 % bolnikov s SCN.
During long-term use cutaneous vasculitis has been reported in 2% of SCN patients.
Pri dolgotrajni uporabi so poročali o kožnem vaskulitisu pri 2% bolnikov s hudo kronično nevtropenijo.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose dependent decrease in blood pressure.
Med vzdrževanjem anestezije povzroči zviševanje koncentracije sevoflurana od odmerka odvisno zniževanje krvnega tlaka.
During maintenance of anaesthesia, increasing the concentration of sevoflurane produces a dose- dependent decrease in blood pressure.
Med vzdrževanjem anestezije povzroči zviševanje koncentracije sevoflurana od odmerka odvisno zniževanje krvnega tlaka.
during neurological surgery to prevent leakage of the fluid surrounding the brain (called cerebrospinal fluid or CSF).
pri nevrokirurških posegih za preprečevanje puščanja tekočine, ki obdaja možgane (imenovane cerebrospinalna tekočina).
During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes.
UV predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
During or after injection: The skin is wet.
Med injiciranjem ali po njem: Koža je mokra.
During or after injection: The status light is flashing orange rapidly and the administration system has stopped (motor sound stopped).
Med injiciranjem ali po njem: Kontrolna lučka hitro utripa oranžno in aplikacijski sistem se je ustavil (zvok motorja je utihnil).
During or after serious illness
Med resno boleznijo ali po njej
During or after you receive these medicines, you may develop Ovarian Hyper- Stimulation Syndrome (OHSS).
Med jemanjem teh zdravil ali po tem lahko pride do sindroma hiperstimulacije jajčnikov (OHSS).
During or following ovarian stimulation an ovarian hyperstimulation syndrome can occur.
Med ovarijsko stimulacijo ali po njej se lahko pojavi sindrom ovarijske hiperstimulacije.
During or within 24 hours of the infusion, you may develop very common symptoms such as chills, fever, tiredness, feeling weak, headache, feeling sick (nausea), being sick (vomiting), muscle ache, and dizziness,.
Med infundiranjem ali v 24 urah po njem se bodo morda pojavili zelo pogosti simptomi, na primer mrzlica, zvišana telesna temperatura, utrujenost, občutek šibkosti, glavobol, občutek slabosti (navzea), slabost (bruhanje), bolečine v mišicah in omotica.
During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.
Med 14-dnevno peroralno uporabo 200 mg ali 300 mg dvakrat na dan pri bolnikih, ogroženih z aspergilozo (v glavnem bolnikih z malignimi novotvorbami limfatičnega ali hematopoetskega tkiva), so se opazovane farmakokinetične značilnosti, hitra in konstantna absorpcija, kopičenje in nelinearna farmakokinetika, ujemale s tistimi, opazovanimi pri zdravih osebah.
During Orgalutran treatment the average incidence of LH rises (> 10 IU/l) with concomitant progesterone rise (> 1 ng/mL) was 0.3 - 1.2 % compared to 0.8 % during GnRH agonist treatment.
Med zdravljenjem z zdravilom Orgalutran je bila povprečna incidenca zvišanja vrednosti LH (> 10 i.e./l) s sočasnim zvišanjem vrednosti progesterona (> 1 ng/ml) 0,3 - 1,2 % v primerjavi z 0,8 % med zdravljenjem z agonistom GnRH.
During period A, 74% were taking methotrexate (mean dose at study entry,
Med obdobjem A je 74% bolnikov prejemalo metotreksat (srednji odmerek ob vstopu v študijo 13,2 mg/m2/teden).
During Period B, the time to disease flare for the patients randomized to placebo was significantly shorter than for those randomized to abatacept (primary endpoint, p=0.0002; log-rank test).
Med obdobjem B študije je bil čas do poslabšanja bolezni pri bolnikih, ki so bili randomizirani na placebo, pomembno krajši kot pri bolnikih, ki so bili randomizirani na abatacept (primarni opazovani dogodek, p=0,0002; log-rank test).
During placebo-controlled studies the following was detected:
V s placebom kontroliranih študijah so ugotovili naslednje:
During pomalidomide treatment
med zdravljenjem s pomalidomidom,
During pomalidomide treatment (including dose interruptions)
med zdravljenjem s pomalidomidom (vključno s prekinitvami odmerjanja)
During post marketing experience, hypersensitivity reactions with very rare occurrence of fatal outcome, have been reported in association with trabectedin administration either alone or in combination with PLD (see sections 4.3 and 4.4).
V okviru izkušenj v obdobju trženja je prišlo do preobčutljivostnih reakcij z zelo redkim nastopom smrtnega izida, o katerih so poročali v povezavi z dajanjem trabektedina samega ali v kombinaciji s PLD (glejte poglavji 4.3 in 4.8).
During post-marketing use of Kineret, thrombocytopenia has been reported, including occasional case reports indicating severe thrombocytopenia (i.e. platelet counts <10 x109/L).
V času uporabe po začetku trženja zdravila Kineret so poročali o trombocitopeniji, vključno s posameznimi primeri, ki so kazali na hudo trombocitopenijo (tj. število trombocitov <10 x109/l)